Evidence map›Paper›PMID 41356181›Full record

ArticleTheranostics2026

An organolutetium nanosensitizer synergizes with PARP inhibition to unleash STING-mediated immunity for low-dose radioimmunotherapy.

Bingchun Zeng, Kai Ling, Qingpeng Yuan, Zeyang Chen, Guangrong Zhang, Wenyue Kang, Xuanjun Zheng, Chuanghong Liao, Youqing Mai, Zhongjie Huang and 3 more

Abstract read
In one paragraph

Article in Theranostics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Bingchun ZengDepartment of Radiation Oncology, Cancer Hospital of Shantou University Medical College, Shantou 515041, China.
Kai LingDepartment of Radiation Oncology, Cancer Hospital of Shantou University Medical College, Shantou 515041, China.
Qingpeng YuanDepartment of Radiation Oncology, Cancer Hospital of Shantou University Medical College, Shantou 515041, China.
Zeyang ChenDepartment of Radiation Oncology, Cancer Hospital of Shantou University Medical College, Shantou 515041, China.
Guangrong ZhangDepartment of Radiation Oncology, Cancer Hospital of Shantou University Medical College, Shantou 515041, China.
Wenyue KangDepartment of Pharmacology, Shantou University Medical College, Shantou 515041, China.
Xuanjun ZhengDepartment of Pharmacology, Shantou University Medical College, Shantou 515041, China.
Chuanghong LiaoDepartment of Pharmacology, Shantou University Medical College, Shantou 515041, China.
Youqing MaiDepartment of Pharmacology, Shantou University Medical College, Shantou 515041, China.
Zhongjie HuangDepartment of Radiology, Shenzhen Maternity and Child Health Care Hospital, Shenzhen 518100, China.
Ruibin HuangDepartment of Radiology, The First Affiliated Hospital of Shantou University Medical College, Shantou 515041, China.
Tiantian ZhaiDepartment of Radiation Oncology, Cancer Hospital of Shantou University Medical College, Shantou 515041, China.
Hongyan JiangDepartment of Radiation Oncology, Cancer Hospital of Shantou University Medical College, Shantou 515041, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

LutetiumMembrane ProteinsNanoparticlesPoly(ADP-ribose) Polymerase InhibitorsRadiation-Sensitizing AgentsRadioimmunotherapyTriple Negative Breast NeoplasmsAnimalsCell Line, TumorDNA DamageFemaleHumansMicePhthalazinesPiperazinesReactive Oxygen SpeciesLutetiumMembrane ProteinsolaparibPhthalazinesPiperazinesPoly(ADP-ribose) Polymerase InhibitorsRadiation-Sensitizing AgentsReactive Oxygen SpeciesSTING1 protein, humanSTING ProteincGAS-STING pathwaylow-dose radioimmunotherapyorganolutetium nanosensitizerPARP inhibitiontriple-negative breast cancer (TNBC)

Identifiers

PMID41356181
PMCPMC12680527

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.